Anticarcinogenic and antiplatelet effects of carvacrol

Experimental Oncology

Volumn 28, Issue 2, 2006, Pages 121-125

  Karkabounas, S ^a   Kostoula, O K ^a,b   Daskalou, T ^a   Veltsistas, P ^b   Karamouzis, M ^d   Zelovitis, I ^a   Metsios, A ^a   Lekkas, P ^a   Evangelou, A M ^a   Kotsis, N ^a   Skoufos, I ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Epirus Institute of Technology Arta   (Greece)

^d ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Carvacrol; Experimental carcinogenesis; GPIIb IIIa platelet receptors; Leiomyosarcoma cells; Origanum vulgaris; Platelet aggregation

Indexed keywords

BENZO[A]PYRENE; CARVACROL; FIBRINOGEN RECEPTOR; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; MALE; METABOLITE; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; THROMBOCYTE AGGREGATION;

ANIMALS; ANTICARCINOGENIC AGENTS; BENZO(A)PYRENE; BLOOD PLATELETS; CELL PROLIFERATION; LEIOMYOSARCOMA; MALE; MONOTERPENES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; THROMBOXANE B2;

EID: 33746555425     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kintzios SE. Oregano: the genera Origanum and Lippia. Kintzios Se, ed. New York: Taylor and Francis, 2002; 277 p.
2. Aligiannis N, Kalpoutzakis E, Mitaki S, Chinou IB. Composition and antimicrobial activity of the essential oils of two Origanum species. J Agricul Food Chem 2001; 49: 4168-70.
3. Sokmen M, Serkedjieva J, Daferera D, Gulluce M, Polissiou M, Tepe B, Akpulat HA, Sahin F, Sokmen A. In vitro antioxidant, antimicrobial and antiviral activities of the essential oil and various extracts from herbal parts and callus cultures of Origanum acutidens. J Agricul Food Chem 2004; 52: 3309-2.
4. Friedman M, Henika PR, Mandrell RE. Bactericidal activities of plant essential oils and some of their isolated constituents against C. jejuni, E. coli, L. monocytogenes and S. enteritica. J Food Prot 2002; 65: 1545-60.
5. Nastro A, Blanco AR, Cannatelli MA, Enea V, Flamini G, Morelki J, Sudano Roccano A, Alonzo V. Susceptibility of methicillin-resistant staphylococci to oregano essential oil, carvacrol and thymol. FEBS Lett 2004; 230: 191-5.
6. Sokovic M, Tzakou O, Pitarokili D, Couladis M. Antifungal activities of selected aromatic plants growing wild in Greece. Nahrung 2002; 46: 312-20.
7. Manohar V, Ingram C, Gray J, Talpur NA, Echard BW, Bagchi D, Preuss HG. Antifungal activities of origanum oil against Candida albicans. Mol Cell Biochem 2001; 228: 111-7.
8. Ruberto G, Baratta MT, Deans SG, Dorman HJ. Antioxidant and antimicrobial activity of Foeniculum vulgare and Crithmum maritimum essential oils. Planta Med 2000; 66: 687-93.
9. Alma MH, Mavi A, Jildirim A, Diprak M, Hirata T. Screening chemical composition and in vitro antioxidant and antimicrobial activities of the essential oils from Oreganum Synaceum L growing in Turkey. Biol Pharm Bul 2003; 26: 1725-9.
10. Karkabounas S, Sofis G, Evangelou A. Implication of free radicals in platelet aggregation; antiplatelet effects of free radical scavengers ex vivo. Epith Klin Farmacol Farmakokin 1996; 10: 84-1.
11. Karkabounas S, Karabetsos D, Gogos Ch, Beka A, Evangelou, A. The platelet function modification by chemical carcinogenesis inhibitors. Thromb Haemost 1997; 1: 469.
12. Evangelou A, Malamas M, Vezyraki P, Karkabounas S. Is epinephrine-induced platelet aggregation autoregulated by its metabolic degradation products in vivo? In Vivo 1998; 12: 321-6.
13. Kallistratos G, Evangelou A, Agnantis N, Fasske E, Karkabounas S, Donos A. Enhancement of the antineoplastic effect of anticarcinogens on benzo[a]pyrene-treated Wistar rats, in relation to their number and biological activity. Cancer Lett 1994; 82: 153-65.
14. Evangelou A, Kalpousos G, Karkabounas S, Liasko R, Nonni A, Stefanou D, Kallistratos G. Dose-related preventive and therapeutic effects of antioxidants - anticarcinogens on experimentally induced malignant tumors in Wistar rats. Cancer Let 1997; 115: 105-1.
15. Liasko R, Kabanos T, Karkabounas S, Malamas M, Tasiopoulos A, Stefanou D, Collery P, Evangelou A. Beneficial effects of a Vanadium complex with cysteine, administrated at low doses of benzo[a]pyrene - induced leiomyosarcomas in Wistar rats. Anticancer Res 1998; 18: 3609-4.
16. Karkabounas S, Binolis J, Zelovitis J, Kotsis N, Charalabopoulos A, Avdikos A, Zouridakis A, Liasko R, Giannakopoulos X, Charalabopoulos K. Inhibition and modification of benzo[a]pyrene-induced chemical carcinogenesis by ascorbic acid alone or in combination with a-tocopherol in Wistar rats. Exp Oncol 2002; 24: 274-8.
17. Vargaftig BB, Chignard M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol 1981; 30: 263-71.
18. McManus LM, Hanahan DJ, Pinckard N. Human platelet activation by acetyl glyceryl ether phosporylcholine. J Clin Invest 1981; 67: 903-6.
19. Benedetto C, Mc Donalt-Gibsor RC, Nigam S, Slater TF. Prostaglandins and related substances. A practical approach. Oxford IRL Press LTD. 1987.
20. Patrone C, Pesca BA. Radioimmunoassay in basic and clinical pharmacology. Handbook of experimental pharmacology. Springer - Verlag, Berlin. 1987; 82.
21. Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 1980; 20: 947-57.
22. Hezard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphardt S, Droulle C, Elaerts J, Potron G. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haem 1999; 81: 869-3.
23. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-8.
24. Aeschbach R, Loliger J, Scott BC, Murcia A, Butler J, Halliwell B, Aruoma OI. Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chem Toxicol 1994, 32: 31-6.
25. Mishin UM, Thomas PE. Characterization of hydroxyl radicals formation by microsomal enzymes using a water soluble trap, terephthalate. Biochem Pharmacol 2004; 68: 747-52.
26. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Res 2004; 10: 577-88.
27. Tries S, Laufer S, Radziwon P, Breddin HK. Antithrombotic and platelet function inhibiting effects of ML 3000, a new anti-inflammatory drug with Cox/5-LOX inhibitory activity. Inflamm Res 2002; 51: 129-34.
28. Nie D, Tang K, Szekeres K, Trikha M, Honn KV. The role of eicosanoids in tumor growth and metastasis. Ernst Res Found Workshop. 2000, 31: 201-17.
29. Chang SJ, Lin JS, Chen HH. Alpha-tocopherol down regulates the expression of GpIIb promoter in HEL cells. Free Rad Biol Med 2000; 15: 202-20.